Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Uterine Neoplasms

• Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
• Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
• A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
• AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
• A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors
• EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
• Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
• A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
• Niraparib in High-grade Endometrial Cancer Trial
• A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
• A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
• Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
• Effect of Hemp-CBD on Patients With CIPN
• Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
• PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
• Misoprostol as a Treatment for Endometrial Polyps in Infertile Patients
• Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study
• Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
• PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46
• Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
• Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
• MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
• Vasopressin Injection Versus Misoprostol During Hysteroscopic Myomectomy In Reducing Blood Loss And Operation Time.
• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
• Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
• Dydrogesterone in the Treatment of Endometrial Polyps
• Effect of Anesthetic Agents on Optic Nerve Sheath Diameter
• Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer
• AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in
• Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
• Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
• Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
• Study of NEO-201 in Solid Tumors Expansion Cohorts
• Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.
• A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
• Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
• Endometrial Polyps Regression With Progesterone Therapy
• Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
• A Study of Nivolumab in Selected Uterine Cancer Patients
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
• Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
• Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer
• Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines
• VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer
• Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
• Efficacy of the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers
• A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
• The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection
• Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
• A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
• Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
• Pembro/Carbo/Taxol in Endometrial Cancer
• Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen
• Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
• Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
• Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases
• High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection
• Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
• Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
• Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
• Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
• Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
• Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
• Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
• A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
• Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
• Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management.
• Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
• Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
• Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
• Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
• Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
• Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
• A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
• Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
• Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
• A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
• Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
• Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
• Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
• Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
• Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
• Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
• Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
• Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
• Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
• Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
• Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
• Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
• AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
• Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
• Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
• Study of D-Methadone in Patients With Chronic Pain
• A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus
• A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
• Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
• Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
• Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
• Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy
• Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
• Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
• Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
• Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
• Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
• Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery
• Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
• A Trial for Patients With Advanced/Recurrent Endometrial Cancer
• A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation
• Safety of Antioxidants During GYN Cancer Care
• Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
• Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
• Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
• A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
• Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
• Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
• A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers
• A Trial for Patients With Advanced/Recurrent Cervical Cancer
• A Trial for Patients With Gestational Trophoblastic Disease
• Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours
• Uterine Papillary Serous Cancer (UPSC) Trial
• Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
• Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
• Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
• Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
• Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
• Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
• Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
• Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
• Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer